GleamWall
中文EN

TNXP Tonix Pharmaceuticals Holding Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1430306 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY318.0%
TTM net income YoY-82.4%
TTM EPS YoY-104.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin89.3%
Operating margin-436.3%
Net margin-420.4%
FCF margin-395.0%
EBITDA margin-431.0%

Returns

ROE-84.1%
ROA-73.1%
ROIC (approx.)-387.9%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets17.7%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue11.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$17.23M$13.54M$6.88M$5.39M$3.29M$2.00M$2.43M$2.58M
Cost of revenue$1.25M$703,000$1.58M$1.06M$1.37M$3.27M$943,000$1.18M
Gross profit$15.98M$12.84M$5.30M$4.33M$1.92M-$1.27M$1.49M$1.40M
R&D expense$25.82M$19.42M$18.21M$16.94M$9.29M$10.82M$7.44M$8.30M
SG&A expense$45.59M$35.96M$28.62M$35.68M$25.70M$16.20M$10.10M$15.58M
Operating income-$55.43M-$42.53M-$41.54M-$48.29M-$33.07M-$28.30M-$16.05M-$22.48M
Interest expense———$0———$280,000
Net income-$53.33M-$40.55M-$40.19M-$46.91M-$32.01M-$28.27M-$16.83M-$22.11M
EBITDA-$54.83M-$41.94M-$40.98M-$47.80M-$32.67M-$27.80M-$15.56M-$21.98M
EPS (basic)-2.89-2.44-2.93—-3.59-3.86-2.84—
EPS (diluted)-2.89-2.44-2.93—-3.59-3.86-2.84—
Weighted avg. shares (diluted)18.44M16.64M13.71M—8.92M7.33M5.93M—
Balance sheet
Cash & equivalents$162.79M$176.23M$185.47M$207.64M$191.35M$126.24M$131.72M$99.68M
Receivables$14.60M$11.80M$8.82M$6.27M$3.48M$2.32M$3.31M$3.68M
Inventory———————$8.41M
Current assets$192.13M$203.43M$207.17M$228.88M$208.07M$143.53M$149.57M$119.00M
PP&E, net$44.89M$44.76M$44.89M$44.46M$42.57M$42.34M$41.77M$42.25M
Intangibles$120,000$120,000$120,000$120,000$120,000$120,000$120,000$120,000
Total assets$242.43M$254.09M$257.91M$277.17M$252.44M$187.36M$192.87M$162.89M
Current liabilities$42.03M$30.79M$29.65M$30.84M$21.03M$19.06M$12.15M$18.31M
Short-term debt———————$2.82M
Long-term debt———————$4.67M
Total debt———————$7.49M
Total liabilities$42.94M$31.81M$30.77M$32.02M$21.30M$19.36M$12.47M$23.33M
Shareholders' equity$199.49M$222.28M$227.14M$245.15M$231.14M$168.00M$180.40M$139.56M
Net debt———————-$92.19M
Shares outstanding19.15M16.79M14.21M12.79M10.17M7.55M6.88M4.39M
Cash flow statement
Operating cash flow-$41.07M-$42.24M-$42.32M-$39.65M-$28.78M-$14.83M-$16.58M-$14.63M
Capital expenditure$603,000$587,000$1.69M$1.87M$962,000$527,000$6,000$3,000
Free cash flow-$41.68M-$42.83M-$44.01M-$41.52M-$29.74M-$15.36M-$16.59M-$14.63M
Investing cash flow-$603,000-$587,000-$1.69M-$1.02M-$962,000-$2.54M-$6,000-$3,000
Financing cash flow$28.28M$33.51M$20.20M$59.14M$94.86M$10.99M$49.53M$85.15M
Depreciation & amortization$600,000$600,000$555,000$488,000$400,000$500,000$493,000$496,000
Stock-based compensation$2.29M$2.26M$1.97M$1.79M$1.92M$1.42M$882,000$894,000
Share buybacks———$7.81M$0$2.90M$3.05M—

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.